These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 15082672)

  • 1. Acute congestive heart failure induced by rofecoxib.
    Campbell RJ; Sneed KB
    J Am Board Fam Pract; 2004; 17(2):131-5. PubMed ID: 15082672
    [No Abstract]   [Full Text] [Related]  

  • 2. [Probable cardiac failure due to rofecoxib].
    García Nicolás FJ
    Aten Primaria; 2005 Apr; 35(6):325-6. PubMed ID: 15826518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs: population based study.
    Hudson M; Richard H; Pilote L
    BMJ; 2005 Jun; 330(7504):1370. PubMed ID: 15947399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study.
    Mamdani M; Juurlink DN; Lee DS; Rochon PA; Kopp A; Naglie G; Austin PC; Laupacis A; Stukel TA
    Lancet; 2004 May; 363(9423):1751-6. PubMed ID: 15172772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. COX-2 inhibitors and risk of heart failure.
    Kammerl MC; Debler J; Riegger GA; Krämer BK
    Lancet; 2004 Oct 23-29; 364(9444):1486-7; author reply 1487. PubMed ID: 15500886
    [No Abstract]   [Full Text] [Related]  

  • 6. Severe cholestasis and acute renal failure related to rofecoxib.
    Linares P; Vivas S; Jorquera F; Olcoz JL; de Leon B; Oritz de Urbina J
    Am J Gastroenterol; 2004 Aug; 99(8):1622-3. PubMed ID: 15307886
    [No Abstract]   [Full Text] [Related]  

  • 7. Simultaneous presentation of rofecoxib-induced acute hepatitis and acute interstitial nephritis.
    Haider M; Gain E; Khadem G; Pilmore H; Yun K; Jayasinghe N; Walker R
    Intern Med J; 2005 Jun; 35(6):370-2. PubMed ID: 15892770
    [No Abstract]   [Full Text] [Related]  

  • 8. Lessons from the withdrawal of rofecoxib.
    Dieppe PA; Ebrahim S; Martin RM; Jüni P
    BMJ; 2004 Oct; 329(7471):867-8. PubMed ID: 15485938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blood pressure control and rates of edema following the administration of the cyclooxygenase-2 specific inhibitors celecoxib versus rofecoxib in patients with systemic hypertension and osteoarthritis.
    Weaver A; Alderman M; Sperling R
    Am J Cardiol; 2003 May; 91(10):1291-2. PubMed ID: 12745131
    [No Abstract]   [Full Text] [Related]  

  • 10. Lithium interaction with the cyclooxygenase 2 inhibitors rofecoxib and celecoxib and other nonsteroidal anti-inflammatory drugs.
    Phelan KM; Mosholder AD; Lu S
    J Clin Psychiatry; 2003 Nov; 64(11):1328-34. PubMed ID: 14658947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. COX-2 selective non-steroidal anti-inflammatory drugs and cardiovascular disease.
    Ray WA; MacDonald TM; Solomon DH; Graham DJ; Avorn J
    Pharmacoepidemiol Drug Saf; 2003; 12(1):67-70. PubMed ID: 12616850
    [No Abstract]   [Full Text] [Related]  

  • 12. Rofecoxib-induced pseudoporphyria.
    Markus R; Reddick ME; Rubenstein MC
    J Am Acad Dermatol; 2004 Apr; 50(4):647-8. PubMed ID: 15034522
    [No Abstract]   [Full Text] [Related]  

  • 13. Tolerability of rofecoxib.
    Asero R
    Allergy; 2001 Sep; 56(9):916-7. PubMed ID: 11551261
    [No Abstract]   [Full Text] [Related]  

  • 14. The new COX-2 inhibitors: rofecoxib (Vioxx) and celecoxib (Celebrex).
    Wynn RL
    Gen Dent; 2000; 48(1):16-20. PubMed ID: 11199547
    [No Abstract]   [Full Text] [Related]  

  • 15. Probable rofecoxib-induced thrombocytopenia.
    Kentos A; Robin V; Lambermont M; Jurdan M; Pignarelli M; Feremans W
    Rheumatology (Oxford); 2003 May; 42(5):699-700. PubMed ID: 12709555
    [No Abstract]   [Full Text] [Related]  

  • 16. Rofecoxib and the risk of adverse upper gastrointestinal effects.
    Whitney E
    JAMA; 2000 Apr; 283(15):1960; author reply 1961. PubMed ID: 10789660
    [No Abstract]   [Full Text] [Related]  

  • 17. Non-steroidal anti-inflammatory drugs in orofacial pain management--an update.
    van der Bijl P; van der Bijl P
    SADJ; 2002 Aug; 57(8):328-31. PubMed ID: 12428528
    [No Abstract]   [Full Text] [Related]  

  • 18. [Gynecomastia secondary to rofecoxib].
    Martínez JA; Tejada González P; Gutiérrez Sanpedro N; González Blanco P
    Med Clin (Barc); 2002 Jun; 118(20):798-9. PubMed ID: 12049701
    [No Abstract]   [Full Text] [Related]  

  • 19. [Extreme sinus bradycardia (30/min) with acute right heart failure under tizanidine (Sirdalud). Possible pharmacological interaction with rofecoxib (Vioxx)].
    Kick A; Bertoli R; Moschovitis G; Caduff Janosa P; Cerny A
    Med Klin (Munich); 2005 Apr; 100(4):213-6. PubMed ID: 15834531
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rofecoxib and the risk of adverse upper gastrointestinal effects.
    Freston J
    JAMA; 2000 Apr; 283(15):1960; author reply 1961. PubMed ID: 10789659
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.